Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

How drug prices are manipulated

Steven Reidbord, MD
Meds
September 30, 2022
33 Shares
Share
Tweet
Share

I wondered whether to recommend Nuedexta for my elderly relative with worsening Alzheimer’s disease and daily spontaneous crying. Often she would deny feeling sad and couldn’t account for her sobbing.   Avanir Pharmaceuticals released Nuedexta in 2010 to treat pseudobulbar affect: involuntary emotional outbursts due to certain neurologic conditions or brain injury. I wasn’t sure if these crying bouts qualified as pseudobulbar affect. But my biggest hesitation was the breathtaking price of the drug.

Nuedexta is a “fixed-dose combination” (FDC) medication containing dextromethorphan (DXM) and quinidine. The former is an active ingredient in over-the-counter cough syrup, the latter a century-old antiarrhythmia medication. Both are very inexpensive, and DXM doesn’t even require a prescription. Yet, according to GoodRx, the average retail price of Nuedexta is nearly $1700 per month. There’s no generic equivalent yet, although there may be soon.

It’s impossible to comparison-shop for novel prescription drugs like Nuedexta.  Patent protection and “non-patent exclusivities” enforce monopolies: no company can sell the same product generically or under another brand name for 20 years after a drug is invented, or about ten years after it hits the marketplace. Justified as a way to recoup development costs, pharmaceutical companies often manipulate these price protections to maximize profits.

1. How to win at Monopoly: Mix it up. One way is to create a new, pricey FDC medication, like Nuedexta, out of two or more cheap generics. To take another example, the FDA approved Auvelity last month to treat major depression. It’s an FDC that combines DXM — the very same cough suppressant — with bupropion, a common generic antidepressant. Auvelity reportedly works faster than conventional antidepressants. The manufacturer has not yet announced a price, but it’s safe to assume it will be far higher than that of its generic components.

This isn’t a new practice. Triavil (1962) combines the antidepressant amitriptyline and the antipsychotic perphenazine. Adderall (1996) combines several generic amphetamines. Symbyax (2003) mixes the antidepressant fluoxetine with the antipsychotic olanzapine — an updated Triavil, in a way.

Outside of psychiatry, it’s easier to justify some FDC formulations. Oral contraceptives combine two hormones, estrogen and progestin. Antiretroviral FDC drugs revolutionized AIDS treatment. The novel FDC Paxlovid uniquely benefits COVID-19 patients.

2. How to win at Monopoly: Find a new use. Another way to game the system is to obtain FDA approval to market an old medication for a new use. It’s the same drug with a fancy new name, packaging, and price. Its new use may not even be particularly novel: it may be for a condition that doctors already treated with the generic drug “off label.”

For example, doxepin has been around since 1969 as an antidepressant. Long available as an inexpensive generic in capsules of 10 to 150 mg, it’s never been popular because it’s too sedating. In fact, doctors occasionally prescribed it “off label” for insomnia, not depression. Turning a bug into a feature, in 2010 Currax Pharmaceuticals rebranded doxepin in low-dose 3 and 6 mg tablets as the patent-protected, FDA-approved sleeping aid Silenor.

According to GoodRx, the average retail price of Silenor is over $600 per month. There was no direct competition until 2020, although generic doxepin remained available. Of course, splitting a 10 mg capsule at home is hard to make a 3 or 6 mg dose for insomnia. Now with generic competition — about 1/4 the price of the brand name, but still many times more expensive than the larger capsules — Currax strongly urges everyone to insist on brand-name Silenor.

This is hardly a lone case. GlaxoSmithKline patented and released Zyban (1997) for smoking cessation to extend its monopolistic pricing for sustained-release bupropion. Zyban is exactly the same medication, at the same dosage, that was losing its patent protection as the antidepressant Wellbutrin SR.  Eli Lilly likewise patented and released Sarafem (2000) for premenstrual symptoms to extend its monopolistic pricing for fluoxetine. Sarafem is exactly the same medication that was losing its patent protection as the antidepressant Prozac.

3. How to win at Monopoly: Tweak it. A third and very common way to extend monopolistic pricing is to tweak an existing medication just enough to justify a new patent. Lexapro (2002) supplanted the older Celexa, even though both are citalopram. The difference is chemically arcane: Lexapro is the S-enantiomer, perhaps with fewer side effects compared to the racemic compound in Celexa. Pristiq (2008) contains desvenlafaxine, an active metabolite that is arguably a minor improvement over venlafaxine in the older Effexor. Lybalvi (2021) combines generic olanzapine with a new medication samidorphan to decrease some of olanzapine’s side effects.

Do these updates justify the premium cost of the brand names (while they are still patent-protected) over the generics? That’s a judgment call — not in my opinion, although many of my colleagues think so.

People or profit?

Clearly, many new drugs mainly serve business interests, not health care. A visiting Martian might ask: Why didn’t the FDA simply announce that generic bupropion helps with smoking cessation, and generic fluoxetine with PMS? Why didn’t the FDA have doctors tell patients to take non-prescription DXM with their prescription bupropion for depression? Or take it with prescription quinidine to treat pseudobulbar affect? Why didn’t the FDA advise manufacturers to make generic doxepin in smaller dosages?

We Earthlings know why. If the federal government conducted its product research, it could make these recommendations to improve public health, not maximize profit. Instead, on this planet, profit drives drug development. Indeed, when a clearly needed medication is unprofitable for private enterprise, the government steps in and pays a company to develop the “orphan drug.” It’s a clear illustration that business goals and health needs aren’t the same.

My relative with dementia took Nuedexta for a couple of weeks. It had no effect and was discontinued, leaving about $800 worth unused. In her case, no one went broke helping Avanir recoup its investment. Other families are not so fortunate.

More recently, I evaluated a patient with chronic depression. Over many years she’d tried nearly every class of antidepressant several times, as well as various antidepressant “augmenting” medications and mood stabilizers (and, yes, psychotherapy). As luck would have it, she’s currently taking maximum doses of bupropion. Before sending her off for more esoteric treatment, I suggested she add cough syrup containing DXM, 20 mg per day, and call me back in ten days. Auvelity isn’t available yet — not that I’d be inclined to prescribe it even if it were.

Steven Reidbord is a psychiatrist who blogs at Reidbord’s Reflections.

Image credit: Shutterstock.com

Prev

Physician contract horror stories

September 30, 2022 Kevin 0
…
Next

My postpartum blood pressure spike [PODCAST]

September 30, 2022 Kevin 0
…

Tagged as: Medications

Post navigation

< Previous Post
Physician contract horror stories
Next Post >
My postpartum blood pressure spike [PODCAST]

More by Steven Reidbord, MD

  • Which is better: Psychotherapy using video or in-person while wearing masks?

    Steven Reidbord, MD
  • Dopamine fasting, debunked by a psychiatrist

    Steven Reidbord, MD
  • Should the telemedicine boom persist after the COVID-19 pandemic?

    Steven Reidbord, MD

Related Posts

  • Why is the government so scared of directly negotiating drug prices?

    Robert Laszewski
  • Negotiating lower drug prices in America: The tradeoffs are worth it.

    Konye Ori
  • Beyond the EpiPen: Irrational drug prices are now pervasive

    Stephen C. Schimpff, MD
  • How hospitals can impact generic drug companies

    Mark Kelley, MD
  • A drug problem in rural Georgia

    Ashish Advani, PharmD
  • Drug ads are a campaign against physician trust

    Judy Salz, MD

More in Meds

  • Telemedicine in the opioid crisis: a game-changer threatened by DEA regulations

    Julie Craig, MD
  • The real cause of America’s opioid crisis: Doctors are not to blame

    Richard A. Lawhern, PhD
  • Can personalized medicine live up to its hype in health care?

    Ketan Desai, MD, PhD
  • The effects of the nationwide stimulant shortage on a private psychiatry practice

    Christine Tran-Boynes, DO
  • Why North American medical cannabis can’t compete globally

    Michael Sassano
  • How were we duped and what can we do about the opioid overdose crisis?

    Ronald A. Zent, MD
  • Most Popular

  • Past Week

    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing COPD management with virtual care solutions [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Tom Brady’s legacy and the importance of personal integrity in end-of-life choices

      Kevin Haselhorst, MD | Physician
    • The hidden truths of hospital life: What doctors wish you knew

      Emily Stanford, DO | Physician
    • 10 commandments of ethical affiliate marketing for physicians

      Aaron Morgenstein, MD & Amy Bissada, DO | Finance
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

CME Spotlights

From MedPage Today

Latest News

  • Journal Shows Its Commitment to Exploring AI in Medicine
  • Do Away With 'Lockout' Period in iPLEDGE, FDA Advisors Urge
  • Cluster Headache, Migraine Linked to Circadian System
  • Smaller Liver Transplant Candidates Wait Longer, Less Likely to Receive Organ
  • A 'Double Whammy' for Gastric Cancer Risk

Meeting Coverage

  • Oral Roflumilast Effective in the Treatment of Plaque Psoriasis
  • Phase III Trials 'Hit a Home Run' in Advanced Endometrial Cancer
  • Cannabis Use Common in Post-Surgery Patients on Opioid Tapering
  • Less Abuse With Extended-Release Oxycodone, Poison Center Data Suggest
  • Novel Strategies Show Winning Potential in Ovarian Cancer
  • Most Popular

  • Past Week

    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • What is driving physicians to the edge of despair?

      Edward T. Creagan, MD | Physician
    • The untold struggles patients face with resident doctors

      Denise Reich | Conditions
    • The psychoanalytic hammer: lessons in listening and patient-centered care

      Greg Smith, MD | Conditions
    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Revolutionizing COPD management with virtual care solutions [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • The real cause of America’s opioid crisis: Doctors are not to blame

      Richard A. Lawhern, PhD | Meds
    • The fight for reproductive health: Why medication abortion matters

      Catherine Hennessey, MD | Physician
    • The vital importance of climate change education in medical schools

      Helen Kim, MD | Policy
    • Nobody wants this job. Should physicians stick around?

      Katie Klingberg, MD | Physician
    • It’s time for C-suite to contract directly with physicians for part-time work

      Aaron Morgenstein, MD & Corinne Sundar Rao, MD | Physician
    • Resetting the doctor-patient relationship: Navigating the challenges of modern primary care

      Jeffrey H. Millstein, MD | Physician
  • Recent Posts

    • Breaking free from a toxic relationship with medicine [PODCAST]

      The Podcast by KevinMD | Podcast
    • Tom Brady’s legacy and the importance of personal integrity in end-of-life choices

      Kevin Haselhorst, MD | Physician
    • The hidden truths of hospital life: What doctors wish you knew

      Emily Stanford, DO | Physician
    • 10 commandments of ethical affiliate marketing for physicians

      Aaron Morgenstein, MD & Amy Bissada, DO | Finance
    • The heart of a Desi doctor: Balancing emotions and resources in oncology

      Dr. Damane Zehra | Physician
    • Safe sex for seniors: Dispelling myths and embracing safe practices [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today iMedicalApps
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

How drug prices are manipulated
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...